NC H330

Adds over 40 new synthetic opioids to Schedule I, including AP-237 variants and numerous U-47700 analogs (such as 2-Naphthyl U-47700, Cyclopropyl U-47700, and difluoro variants)

Creates a new Schedule I category for nitazene derivatives, a class of potent synthetic opioids derived from benzimidazole, with exceptions for commercial manufacturing, medical prescriptions, and recognized research institutions

Expands Schedule I synthetic cannabinoid definitions to include six new structural classes: oxindoles, indole acetamides, indazole acetaldehydes, and pyrazoles, capturing emerging designer drug variants

Adds bromazolam, a designer benzodiazepine, to Schedule I depressants

Makes technical corrections to existing controlled substance listings, including updating chemical names for fentanyl derivatives and correcting spelling errors for anabolic steroids (dehydrochloromethyltestosterone and mesterolone)